Trial reportFrontiers in neurology2025
A multicenter, international, randomized, single-blind, placebo-controlled study of the efficacy and safety of inosine-nicotinamide-riboflavin-succinic acid in the acute period of traumatic brain injury in adults.
Trial report in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04631484 (International, Multicenter, Randomized, Single Blind, Placebo-controlled Study of Efficacy and Safety of CITOFLAVIN® in the Acute Period of Head Injury in Adults), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
International, Multicenter, Randomized, Single Blind, Placebo-controlled Study of Efficacy and Safety of CITOFLAVIN® in the Acute Period of Head Injury in Adults
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The combination of inosine, nicotinamide, riboflavin, and succinic acid (INRSA) has previously demonstrated neuroprotective effect. We aimed to study the efficacy and safety of treatment with INRSA in traumatic brain injury (TBI). Materials and methods: In our multicenter, randomized, placebo-controlled, single-blind clinical trial, we studied TBI patients aged 18-60, diagnosed with cerebral contusion without compression, admission Glasgow Coma Scale (GCS) score of 13-14, and posttraumatic amnesia. The INRSA/placebo was administered intravenously twice daily for 10 days. The primary endpoints were the Galveston Orientation and Amnesia Test (performed on days 2-14), and Glasgow Outcome Scale-Extended (GOS-E; assessed on day 90 via telephone interview). Results: Between November 2020 and May 2024, 166 patients were enrolled, median age 43 (IQR 33-51), 113 (68.5%) males, all with admission GCS 13-14, 123 (74.5%) had closed-type TBI. In the interim analysis, complete recovery (GOS-E category 8) was achieved in 24 (30%) patients in the placebo group and 55 (73%) in the INRSA group. The difference in proportions was 44% (95% CI 0.26; 0.62); experimental treatment increased the odds of complete recovery by 6.53 (95% CI 3.30-13.41) compared to placebo. Based on the pre-specified criteria, the independent data monitoring committee recommended termination of the study due to early demonstration of efficacy by one of the two primary endpoints. Conclusion: Treatment with INRSA was associated with improvement in mild TBI outcome, which represents a new potential option for the pharmacological treatment of non-fatal head injury. Further studies might be of research interest and clinical demand. Clinical trial registration: ClinicalTrials.gov, identifier: NCT04631484; unique protocol ID: CTF-III-CCT-2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.